Abstract
While most inhibitors of histone deacetylases (HDACs) are hydroxamic acid derivatives, several nonhydroxamates have recently been developed as inhibitors and attracted quite a deal of attention. In this review, we present the rational design, inhibitory effect and antiproliferative activity of non-hydroxamate HDAC inhibitors.
Keywords: Histone deacetylase, inhibitor, hydroxamic acid, non-hydroxamate, zinc enzyme, rational drug design, anticancer agent
Mini-Reviews in Medicinal Chemistry
Title: Rational Design of Non-Hydroxamate Histone Deacetylase Inhibitors
Volume: 6 Issue: 5
Author(s): Takayoshi Suzuki and Naoki Miyata
Affiliation:
Keywords: Histone deacetylase, inhibitor, hydroxamic acid, non-hydroxamate, zinc enzyme, rational drug design, anticancer agent
Abstract: While most inhibitors of histone deacetylases (HDACs) are hydroxamic acid derivatives, several nonhydroxamates have recently been developed as inhibitors and attracted quite a deal of attention. In this review, we present the rational design, inhibitory effect and antiproliferative activity of non-hydroxamate HDAC inhibitors.
Export Options
About this article
Cite this article as:
Suzuki Takayoshi and Miyata Naoki, Rational Design of Non-Hydroxamate Histone Deacetylase Inhibitors, Mini-Reviews in Medicinal Chemistry 2006; 6 (5) . https://dx.doi.org/10.2174/138955706776876186
DOI https://dx.doi.org/10.2174/138955706776876186 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Anti-Angiogenic Compounds for Application in Tumor Therapy – COP9 Signalosome-Associated Kinases as Possible Targets
Mini-Reviews in Medicinal Chemistry Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance
Current Drug Targets Anticancer Activity of New Haloalkyl Camptothecin Esters against Human Cancer Cell Lines and Human Tumor Xenografts Grown in Nude Mice
Anti-Cancer Agents in Medicinal Chemistry COX Selectivity and Animal Models for Colon Cancer
Current Pharmaceutical Design In Vivo Beta-Cell Imaging with VMAT 2 Ligands - Current State-of-the-Art and Future Perspectives
Current Pharmaceutical Design The Role of Cytochrome P450 in Herb-Drug Interactions
Current Pharmacogenomics Bortezomib in the Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Proteins for Treatment of Corneal Epithelial Defects
Current Medicinal Chemistry Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer
Current Cancer Drug Targets Curcumin - Properties, Applications and Modification of Structure
Mini-Reviews in Organic Chemistry Chronic Complications of Diabetes Mellitus: A Mini Review
Current Diabetes Reviews The Effect of Polyphenol Consumption on Blood Pressure
Mini-Reviews in Medicinal Chemistry Perspectives on Medicinal Properties of Benzoquinone Compounds
Mini-Reviews in Medicinal Chemistry Compounds from Wild Mushrooms with Antitumor Potential
Anti-Cancer Agents in Medicinal Chemistry Induction of Oral Tolerance with Transgenic Plants Expressing Antigens for Prevention/Treatment of Autoimmune, Allergic and Inflammatory Diseases
Current Pharmaceutical Biotechnology Treating Chronic Hepatitis B: Today and Tomorrow
Current Medicinal Chemistry Hibiscus Sabdariffa Linnaeus (Malvaceae), Curcumin and Resveratrol as Alternative Medicinal Agents Against Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry LAT1 Targeted Delivery of Methionine Based Imaging Probe Derived from M(III) Metal Ions for Early Diagnosis of Proliferating Tumours using Molecular Imaging Modalities
Current Cancer Drug Targets Pain Perception and Management: Where do We Stand?
Current Molecular Pharmacology A New Approach for β-cyclodextrin Conjugated Drug Delivery System in Cancer Therapy
Current Drug Delivery